

# The toxic A $\beta$ oligomer and Alzheimer's disease: an emperor in need of clothes

Iryna Benilova<sup>1,2</sup>, Eric Karran<sup>1</sup> & Bart De Strooper<sup>1,2</sup>

The 'toxic A $\beta$  oligomer' hypothesis has attracted considerable attention among Alzheimer's disease researchers as a way of resolving the lack of correlation between deposited amyloid- $\beta$  (A $\beta$ ) in amyloid plaques—in terms of both amount and location—and cognitive impairment or neurodegeneration. However, the lack of a common, agreed-upon experimental description of the toxic A $\beta$  oligomer makes interpretation and direct comparison of data between different research groups impossible. Here we critically review the evidence supporting toxic A $\beta$  oligomers as drivers of neurodegeneration and make some suggestions that might facilitate progress in this complex field.

Accumulation of abnormally folded proteins is a key histopathological characteristic of many neurodegenerative disorders. In Huntington's disease, the polyglutamine protein huntingtin is present in intranuclear inclusions; in prion disease, infectious prion particles bind to the membrane-bound protein. In Parkinson's disease,  $\alpha$ -synuclein aggregates as Lewy bodies in the cytoplasm of neurons. In Alzheimer's disease, both intra- and extracellular amyloids—that is, neuronal tangles containing phosphorylated tau and amyloid plaques consisting of amyloid peptides (A $\beta$ )—are observed. Thus, aggregates accumulate extracellularly or in the cytoplasm, in the nucleus and at the cell membrane in different diseases.

A plausible generic explanation for the toxicity of intracellular aggregates involves the idea that the sequestration of crucial proteins together with amyloid leads to cellular dysfunction and death. Deregulated proteostasis could initiate and certainly enhance such protein failure. In Alzheimer's disease, tau aggregates occur intracellularly and could indeed theoretically trap functional proteins, such as tau itself, possibly leading to microtubule destabilization or other cellular dysfunction and death. Alzheimer's disease is somewhat unusual, however, in that there are two aggregates—intracellular tau and extracellular A $\beta$ —that potentially could result in neuronal dysfunction and death. A central question in the field is: by what mechanism might extracellular amyloid peptides such as A $\beta$  harm cells? An alternative hypothesis suggests that small soluble oligomeric structures consisting of amyloid peptides can cause cellular toxicity. Metastable oligomeric structures have indeed been described in preparations of amyloid-forming peptides such as  $\alpha$ -synuclein, tau, prion and A $\beta$ . When produced intracellularly, oligomers expose flexible hydrophobic surfaces<sup>1</sup> that might contribute to trapping vital proteins, but they also, when produced extracellularly (as is largely the case for A $\beta$ ), cause potentially toxic alterations of cell membranes<sup>1</sup>. This notion of a toxic A $\beta$  oligomer has been strongly promoted in Alzheimer's

research because it provides potential explanations for the toxicity of the extracellular A $\beta$  peptide and for the lack of a correlation between deposition of insoluble A $\beta$  plaques and neuronal loss: A $\beta$  oligomers might be able to mediate toxicity at some distance from established plaques. Further, they could subtly damage and predispose sensitive neurons to the formation of intracellular tau aggregates. The present avalanche of publications claiming the identification of various toxic A $\beta$  oligomers would indeed seem to support this hypothesis. However, the exact meaning of the term 'toxic A $\beta$  oligomer' is very confusing. This elusive soluble A $\beta$  species is in danger of becoming a way to explain inconsistencies in existing models without applying the scientific rigor needed to make real progress. The burden of proof for this 'invisible toxin' is on the person making the claim, as with the (in)famous teapot of the British philosopher Bertrand Russell.

In this review we investigate the evidence for toxic A $\beta$  oligomers and their role in Alzheimer's disease, the definition of toxic A $\beta$  oligomers and the question of whether it is reasonable to consider toxic oligomers as drug targets.

## The case for oligomers in Alzheimer's disease

The case for a central role of A $\beta$  in the pathogenesis of Alzheimer's disease is very strong<sup>2</sup>. However, the precise role of A $\beta$  in the disease—whether as a trigger of subsequent neuronal death processes, a toxic threshold that needs to be surmounted before neuronal death processes occur or a continual driver of neuronal death—has yet to be clarified<sup>3</sup>. Mutations in the genes encoding either the substrate ( $\beta$ -amyloid precursor protein (*APP*)) or the enzyme (presenilin (*PSEN*)) that generate A $\beta$  are sufficient to cause the disease<sup>4</sup>. The most significant genetic risk factor for late-onset Alzheimer's disease, *APOE4*, affects A $\beta$  clearance<sup>5</sup> or its oligomerization<sup>6</sup>. The alternative hypothesis<sup>7</sup> proposing that loss of function of *PSEN* interferes with synaptic function independently of A $\beta$  does not explain the effects of *APP* mutations, *APP* duplications or *APOE4*. This failure to explain these effects, together with the fact that all studied *PSEN* mutations also affect A $\beta$ , unequivocally points to abnormalities in A $\beta$  generation or clearance as being a primary and seminal cause of Alzheimer's pathology. This compelling genetic evidence for A $\beta$ 's role in Alzheimer's disease does not necessarily imply strong support for

<sup>1</sup>Center for Human Genetics and Leuven Institute for Neurodegenerative Diseases (LIND), University of Leuven, Leuven, Belgium. <sup>2</sup>VIB Center for the Biology of Disease, Leuven, Belgium. Correspondence should be addressed to B.D.S. (bart.destrooper@cme.vib-kuleuven.be).

Published online 29 January 2012; doi:10.1038/nn.3028

the pathological role of A $\beta$  plaques or provide mechanistic support for a role in neuronal death. Indeed, the number of A $\beta$  plaques in the brain does not correlate to the severity of cognitive decrements in patients, and alterations in A $\beta$  metabolism and even amyloid plaques are already present many years before clinical symptoms can be observed<sup>8</sup>. In transgenic mouse models of Alzheimer's disease that overexpress APP and/or presenilin, findings show no correlation between amyloid plaques and cognitive alterations or neurodegenerative changes. Finally, there is no description of an amyloid plaque-only dementia, whereas tau-only pathology can cause neuronal loss in frontotemporal lobar dementia.


How, then, can the relationship between A $\beta$  and cognitive alterations be understood? More than 20 years ago, it was demonstrated *in vitro* that nontoxic monomeric A $\beta$  was converted into a toxic species after incubation for a few days in buffer<sup>9</sup>. Toxicity was associated with the appearance of "high-molecular-weight species" in SDS-PAGE. Atomic force microscopy, ultracentrifugation and gel filtration techniques later demonstrated the presence of "metastable A $\beta$  protofibrils"<sup>10,11</sup> in A $\beta$  preparations generated *in vitro*. These protofibrils have a smaller diameter than amyloid fibrils and high  $\beta$ -sheet content, and they are likely to be on a pathway to amyloid fibril formation. APOJ (encoding clusterin), a genetic risk factor for Alzheimer's disease, was shown to promote such soluble A $\beta$  structures<sup>12</sup>. These and still other oligomeric assemblies<sup>13,14</sup> disturb neurotransmission and can cause cell death *in vitro* and *in vivo*. Several investigators have demonstrated that soluble A $\beta$  oligomeric species can be extracted with saline buffers from the brain tissue of patients with Alzheimer's disease and that the presence of such soluble species is more strongly correlated than amyloid plaques with disease symptoms<sup>15,16</sup>. Finally, at least two clinical mutations in APP itself in the middle of the A $\beta$  peptide<sup>17,18</sup> seem to increase tendency of the mutated A $\beta$  to oligomerize.

These observations support but do not prove the hypothesis that ill-defined soluble A $\beta$  species are involved upstream in the pathogenesis cascade that causes Alzheimer's disease.

### A $\beta$ : from monomer production to plaque assembly

The monomeric A $\beta$  (molecular weight ~4 kDa) is produced mainly in neurons from APP (molecular weight ~120 kDa) via sequential scission by the enzymes  $\beta$ - and  $\gamma$ -secretase (Fig. 1). An alternative  $\alpha$ -secretase pathway operates in other cell types, generating shorter fragments that are thought to be nonamyloidogenic (see ref. 4 for further discussion). For the present debate, it is important to realize that A $\beta$  is a heterogeneous mixture of peptides having different solubility, stability and biological and toxic properties. C-terminal heterogeneity is generated by the  $\gamma$ -secretase itself. This protease cleaves APP at different positions, generating a variety of peptides, of which A $\beta$ 43, A $\beta$ 42, A $\beta$ 40, A $\beta$ 38 and A $\beta$ 37 variants are detected in cell culture and body fluids (A $\beta$  numbering indicates the last C-terminal amino-acid residue and the number of amino acids comprising the peptide, with residue 1 being the amino acid residue aspartyl-1 of the A $\beta$  sequence in APP; see Fig. 1). Additional heterogeneity is generated by enzymatic processes mediated by aminopeptidases, glutaminylcyclase or isomerases (reviewed in ref. 4), and by phosphorylation reactions<sup>19</sup>, resulting in a mix of more than 20 A $\beta$  peptides that all participate to different extents in putative A $\beta$  functions in the normal brain and oligomerization and fibrillization in the Alzheimer's disease-afflicted brain. A $\beta$ 40 is continuously and abundantly produced in both healthy and Alzheimer's-affected brain tissue, whereas other A $\beta$  peptides are continuously produced at lower levels.

The literature devoted to Alzheimer's disease has historically focused on the A $\beta$ 42 species. This peptide was found to be increased



**Figure 1** Generation of A $\beta$  from amyloid precursor protein. The sites of  $\beta$ - and  $\gamma$ -secretase-mediated cleavage are indicated with arrows, and the transmembrane domain of APP is highlighted in gray.  $\gamma$ -cleavage produces a pool of A $\beta$  fragments that vary in length and hydrophobicity. The mutations in A $\beta$  region of APP either increase the total A $\beta$  production (marked in blue), alter A $\beta$  biophysical properties (in black) or affect the A $\beta$  spectrum in both quantitative and qualitative ways (in green).


in cells expressing APP or presenilin harboring mutations associated with familial Alzheimer's disease (FAD). Early literature demonstrated that A $\beta$ 42 provided small "nidi" that initiated amyloid fibril formation robustly, leading to the nucleated polymerization mechanism of A $\beta$  amyloidogenesis<sup>20</sup>. This view has dominated the field, but the focus on A $\beta$ 42 as the disease-causing and fibrillization-inducing agent has biased our understanding of the disease process. Indeed, aggregation and toxic properties are studied with solutions containing a single type of A $\beta$ , but these properties are likely to be strongly influenced by the presence of other A $\beta$  species. A $\beta$ 43, apart from A $\beta$ 42, is increased in certain patients with FAD, whereas shorter A $\beta$  peptides such as A $\beta$ 37 or A $\beta$ 38 are decreased<sup>21</sup>. Finally, evidence is accumulating that polymerization of A $\beta$  is complex and occurs via metastable intermediaries in a process called "nucleated conformational conversion"<sup>22</sup>.

Therefore, qualitative changes in the spectrum of A $\beta$  peptides, more than quantitative increases of individual A $\beta$  peptides, are determining the biophysical and pathobiological properties of what we call A $\beta$ . Minor changes in the levels of long A $\beta$ 42 or A $\beta$ 43, or pyroglutamate-modified A $\beta$ , can drive the seeding of plaques, and, possibly independently, neurotoxicity. The complexity of these processes needs to be accommodated as we consider the transition from normal A $\beta$  production to pathologically relevant A $\beta$  oligomer generation in incipient Alzheimer's disease.

Amyloid plaques might exist apart from or in equilibrium with oligomeric forms of A $\beta$ . They consist of cross- $\beta$ -sheet units of A $\beta$  peptides that are arranged to form amyloid fibrils. Plaques may be considered inert sinks of aberrantly folded proteins, lipids and free metals. But neurons in the vicinity of plaques display dystrophic neurites and synaptic loss, and elevated resting calcium levels are seen in neurons surrounding plaques in mouse models of Alzheimer's disease<sup>23</sup>. This suggests that plaques are not entirely innocuous. A dynamic equilibrium between toxic oligomers and inert fibrils might exist around the plaques, resulting in local 'spillover' of neurotoxic species in surrounding tissue. It is also possible that the presence of these hydrophobic deposits triggers inflammatory processes that result ultimately in neuronal damage.

### Soluble A $\beta$ oligomers: constant change

As Heraclitus observed around 2,500 years ago, "change alone is unchanging." Thus, between the monomeric A $\beta$  and the amyloid A $\beta$  fibrils in the plaques, intermediary soluble oligomers must exist and they might explain the neurotoxicity ascribed to soluble fractions in various experiments. However, the literature provides no clarity as to which of the bewildering list of A $\beta$  oligomer species identified




A couple of important issues should be addressed before we discuss these different A $\beta$  oligomeric species in more detail. One is the ‘SDS resistance’ of the oligomers, which is used as a defining characteristic in most of the relevant literature. Bitan *et al.*<sup>24</sup> have demonstrated that SDS can actually induce artificially oligomerization of A $\beta$ , and Hepler *et al.* applied A $\beta$  oligomers, A $\beta$  fibrils and A $\beta$  monomers to SDS-PAGE and obtained monomer, trimer and tetramers as major bands in each preparation<sup>25</sup>. Therefore, SDS-PAGE is not a reliable method to analyze A $\beta$  oligomers or to make comparisons between different laboratories. Given that every technique has its own limitations, only the combination of SDS-PAGE with other analytical tools (gel filtration, dynamic light scattering, atomic force microscopy) can provide a more precise definition of the species under study. For instance, a 65–80-kDa peak is seen in size-exclusion chromatography of some A $\beta$  oligomer preparations. This peak suggests A $\beta$  species with the mass of a dodecamer, but this fraction actually contains structures of 150–1,000 kDa as detected with multi-angle laser light scattering<sup>25</sup>. A $\beta$  oligomers consist of amphiphilic peptides that might adopt very heterogeneous morphologies explaining their unusual behavior in many analytical methods<sup>25</sup>.

biophysical conditions, recovery of the putative toxic species from the cell culture medium at the end of the experiment and covalent stabilization of the oligomer are only partial remedies to this problem.

Apart from different preparations, many different ‘toxicity’ assays are used to demonstrate biological activity of the A $\beta$  oligomers. Several laboratories use the mitochondrial MTT (tetrazole) test despite serious concerns regarding its validity in view of the nonspecific interference of A $\beta$  peptide with MTT dye reduction<sup>26</sup>. Other cytotoxicity tests<sup>26,27</sup> are probably more reliable when assessing A $\beta$  toxicity. Some groups also measure induction of apoptosis or other markers of cell death. Interestingly, almost all A $\beta$  oligomers show synaptotoxicity as measured by changes in dendritic spine morphology, altered long-term potentiation (LTP) and long-term depression (LTD) in hippocampal slices; effects on neurotransmission in cell culture; or defects in memory and cognition in rodents<sup>13,14,28–33</sup> (see **Table 1** and **Figs. 4** and **5**). These rather subtle synaptic alterations triggered by A $\beta$  in model systems are thought to reflect the early cognition problems seen in people with Alzheimer’s disease, although other investigators consider them a ‘far cry’ from the massive cell loss seen in affected human brain tissue<sup>33</sup>. Acute, widespread cell loss by A $\beta$  would in fact not be expected, as neuronal death manifests only in the advanced form of the disease, which evolves from the incipient pathology over many decades. The A $\beta$  toxicity initiating the early changes in brain tissue must therefore be subtle, and it is probably transient until the damage caused by the A $\beta$  oligomer stress, combined with accumulating tau pathology, results in irreversible neurodegeneration. An alternative view is that the alterations in synaptic processing that can be induced *in vivo* in disease models do not have a human correlate and that the onset of cognitive decline in Alzheimer’s disease occurs when tau-mediated neuronal loss and dysfunction essentially overwhelm ‘cognitive reserve’.

With regard to oligomer identification and characterization, the literature can be divided into two schools of thought: '*in vitro*' and '*ex vivo*'. Each has its own advantages and pitfalls, not all of which are always acknowledged in the literature.

The strongest correlative support for the potential role of soluble A $\beta$  species in Alzheimer's disease comes from work on brain tissue from patients with Alzheimer's. Several investigators have demonstrated that such species can be extracted from affected brain tissue using saline buffers and without detergents<sup>15,16</sup>.



NATURE NEUROSCIENCE VOLUME 15 | NUMBER 3 | MARCH 2012

**Table 1 Major soluble A $\beta$  preparations and deleterious effects associated with them**

| Species   | Structure   | Biological effects  |
|---|---|---|
| A $\beta$ -derived diffusible ligands (ADDL) <sup>13,90,93</sup>  | 3–24-mer<br>Major component, 17 kDa (tetramer)<br>Globular structures<br>2–5-nm height<br>Off-pathway<br>A11-positive   | LTP impairment (500 nM)<br>Tau mis-sorting into dendrites and tau phosphorylation (5 $\mu$ M)<br>Abnormal mitochondrial distribution in neurites caused by impaired tau-dependent axonal transport (800 nM)<br>Cytotoxicity in primary neurons (micromolar concentration)<br>Cognitive impairment in mice |
| A $\beta$ *56 (refs. 39,48)   | 12-mer<br>Globulomers<br>56 kDa<br>A11-positive   | NMDAR-dependent synaptotoxicity<br>Memory deficiency in middle-aged mice<br>Tau phosphorylation: data not available<br>No cytotoxicity<br>Cognitive impairment in rats (micromolar concentration)   |
| A $\beta$ O <sup>69,94,95</sup>   | 15–20-mer<br>Spherical vesicles 2–5 nm<br>A11-positive  | NMDAR-dependent synaptotoxicity<br>Tau phosphorylation: data not available<br>Cytotoxicity in human neuronal cultures (5 $\mu$ M)   |
| A $\beta$ 42 and A $\beta$ 42:40 (3:7) synthetic oligomers <sup>27</sup>  | $\beta$ -sheet enriched<br>Transient on-pathway species<br>A11-positive   | Impairment of synaptic transmission (1 $\mu$ M)<br>Tau phosphorylation (our unpublished data)<br>Cytotoxicity in primary neurons (micromolar concentration)<br>Memory deficiency in mice  |
| Transglutaminase 2-induced oligomers <sup>40</sup>  | Apparently no secondary structure<br>Off-pathway<br>A11-positive (our unpublished data)   | LTP impairment (100 nM)<br>Tau phosphorylation: data not available<br>No cytotoxicity in primary neurons (our unpublished data)   |
| A $\beta$ 42CC protofibrils <sup>88</sup>   | Intramolecular disulfide bond stabilized antiparallel $\beta$ -sheet-based structure that does not propagate into fibrils<br>Weak reactivity with A11                               | Synaptotoxicity (1 $\mu$ M) (our unpublished data)<br>Tau phosphorylation: data not available<br>Caspase-3 activation in human neuroblastoma cells (1–10 $\mu$ M)   |
| Annular protofibrils (APF) <sup>96</sup>  | Off-pathway<br>Form pores, 11–14-nm outer diameter; 2.5–4-nm inner diameter<br>Composed of spherical A11-positive A $\beta$ 42 oligomers assembled in 6 hexamers, (36-mer), 155 kDa | Hypothesized to cause Ca <sup>2+</sup> overload and cytotoxicity (micromolar concentration)   |
| SDS-stable dimers and trimers isolated from WT or FAD <i>hAPP</i> - and WT or FAD <i>PSEN1</i> - and <i>PSEN2</i> -transfected CHO cell culture medium <sup>14,28,30,48,97,98</sup> | 6-, 8- and 12-kDa assemblies<br>Enriched in N-end (Arg5) truncated species<br>Contain A $\beta$ 40 and A $\beta$ 42   | LTP impairment<br>NMDAR and mGluR-dependent LTD facilitation<br>Tau phosphorylation<br>No cytotoxicity<br>Cognitive impairment in mice (low-nanomolar concentrations)   |
| SDS-stable brain-derived dimers <sup>34,49,99</sup> and synthetic dimers (A $\beta$ <sub>1–40</sub> Ser26Cys) <sup>a</sup>  | 8–12-kDa assemblies<br>3–4-nm height<br>No detectable secondary structure   | LTP impairment (100 nM) <sup>b</sup><br>Tau phosphorylation in primary neurons (0.5 nM)<br>No cytotoxicity to primary neurons (micromolar concentration) but toxic to neurons cultured with microglia   |
| SDS-stable amylospheroids (ASPD; synthetic or brain-derived) <sup>36,37,100, a</sup>  | 10–15-nm spherical A $\beta$ assemblies<br>32–150-mers<br>A11-negative  | Synaptic impairment: data not available<br>Tau protein kinase 1/GSK-3 $\beta$ activation (210 nM);<br>NMDAR-independent cytotoxicity in neurons (high-picomolar to low-micromolar concentration). The highest toxicity is ascribed to either 32-mer (7.2 nm) or to ASPD >10 nm                            |

<sup>a</sup>Isolated from brains of humans with Alzheimer's disease. <sup>b</sup>LTP alteration by dimers<sup>34</sup> was later attributed to the dimer-derived  $\beta$ -sheet-containing protofibrils<sup>35</sup>.


Further fractionation of these brain extracts by means of nondenaturing size-exclusion chromatography was performed, and the highest synaptotoxicity in the late-eluting fractions was found correlating with the presence of soluble A $\beta$ <sup>34</sup>. A $\beta$  ran as a dimer in SDS-PAGE and interfered with synaptic function in different paradigms. The authors therefore defined A $\beta$  dimers as the minimal toxic species *in vivo*, but whether the synaptotoxicity observed in their preparations was indeed directly caused by the dimers present in their purified fractions remains unproven. Furthermore, the exact amino acid composition of the putative 'dimeric' species has not been definitively clarified. Additional contamination by unknown protein or lipid, covalent modification of A $\beta$  or the rapid aggregation of the putative dimers into larger structures during assays might provide alternative explanations. The authors confirmed that A $\beta$  dimers made by cross-linking synthetic A $\beta$  were synaptotoxic, although no direct quantitative

comparison with the brain-derived dimers was made. Moreover, in a later study, the authors found that these synthetic dimers rapidly aggregate in metastable protofibrils<sup>35</sup>, suggesting that a more complicated interpretation of the available evidence is needed.

Indeed, apart from the A $\beta$  dimers and trimers<sup>34</sup>, larger A $\beta$  oligomers and structures such as the amylospheroids (ASPD), which are spherical A $\beta$  assemblies of 10–15 nm<sup>36,37</sup>, have been isolated from Alzheimer's-affected brain tissue and suggested by investigators to be the elusive toxic A $\beta$  oligomeric species postulated above.

Experiments using brain tissue from transgenic mice have yielded very controversial results. In the J20 mouse model of Alzheimer's disease, which expresses human APP containing two familial mutations, no clear correlation between memory deficits and the presence of dimers, trimers or other A $\beta$  species could be established<sup>38</sup>. The authors concluded: "These data demonstrate the presence of multiple assembly





**Figure 4** Key steps of A $\beta$ -initiated neurodegenerative cascade according to the amyloid hypothesis. The diagram illustrates the main points of attack that have been described in the literature. It is clear that no consensus exists.

forms of A $\beta$  throughout the life of J20 mice and highlight the difficulty in attributing synaptotoxicity to a single A $\beta$  species<sup>39</sup>. In Tg2576 transgenic mice that overexpress Swedish-mutated human APP, a 56-kDa species called A $\beta$ \*56 was correlated with cognitive deficits<sup>39</sup>. Purified A $\beta$ \*56 caused memory deficits when injected in brains of young rats. An important concern with A $\beta$ \*56 is the presence of 0.1% SDS in the initial extraction buffer<sup>39</sup> because, as discussed, SDS might artificially promote the aggregation of A $\beta$ <sup>24</sup> and could also be a matter of concern when assessing toxicity in cellular or *in vivo* assays.

Overall, the experiments present a very mixed picture: they generally support the existence of a mixture of water-soluble A $\beta$  species that exert synaptotoxicity, but it remains to be clarified whether this toxicity can be specifically associated with dimers, trimers or other assemblies, and whether these assemblies can mediate neurotoxicity in Alzheimer's disease. Probably the most crucial question is the nature and biological relevance of the SDS resistance of the identified dimers, trimers and larger oligomers. If it is a property induced by the presence of SDS, then it is unlikely to be meaningful with respect to the putative pathophysiological role of toxic oligomers. If it can be demonstrated, however, that additional covalent modification is responsible for the conversion of A $\beta$  monomers to these *in vivo* dimers, and if this could be unequivocally correlated with toxicity, then their relevance would be indisputable. For instance, it is possible that A $\beta$  monomers in brain become progressively cross-linked by

transglutaminase<sup>40</sup> or other enzymes, or by oxidation-mediated dityrosine and dihistidine bridge formation<sup>41,42</sup>. A correlation of A $\beta$  neurotoxicity with formation of His and Tyr bridges has, however, been shown only in *in vitro* preparations<sup>41</sup>.

### *In vitro*-generated A $\beta$ oligomers


The advantage of *in vitro* generation of A $\beta$  oligomers lies in the more precisely controlled starting materials: peptides are pure and buffer conditions are defined, which makes them ideal for establishing the conditions that induce the toxic conformation of A $\beta$ . However, this paradigm still faces multiple challenges. In aqueous solutions, A $\beta$  monomer is mostly unstructured, representing a mixture of interconverting conformations rather than a unique fold, and alterations in this mixture may determine the ultimate aggregation pathway<sup>43</sup>. It is, therefore, not surprising that different aggregate morphologies with different biological potencies have been generated from the same peptide<sup>1,37,44</sup>. A $\beta$  oligomers may be metastable intermediates on the pathway to an insoluble, cross- $\beta$ -sheet-based fiber. Authors have suggested that certain oligomers are off-pathway species that have different secondary structures and do not further aggregate to amyloid fibers (Table 1 and Fig. 3), but, as discussed, it remains to be seen how stable such aggregates are *in vivo*.

The *in vitro*-generated A $\beta$  oligomeric species meet, to a greater or lesser extent, the general criteria for a pathogenic protein species<sup>45</sup>: (i) their stability and/or rate of formation are sensitive to disease-associated mutations; (ii) they can also be generated from the wild-type protein (because Alzheimer's disease is predominantly sporadic); and (iii) they can be linked to a potential pathogenic mechanism. However, it is not clear whether these *in vitro*-generated species occur *in vivo* or which species are the more relevant ones for the understanding of Alzheimer's disease.

A major criticism that can be leveled at many of the experiments using *in vitro*-reconstituted toxic A $\beta$  oligomers is that high concentrations (micromolar) of A $\beta$  monomers are needed to see the transition from monomer to (toxic) oligomer. Although it has been argued that these 'nonphysiological' concentrations are unlikely to occur *in vivo*, cell culture experiments have shown that A $\beta$  can become concentrated by more than two orders of magnitude to reach micromolar concentrations in acidic vesicular compartments<sup>46</sup>.

Another important point of criticism is that many publications claim that *in vitro*-generated oligomers seem less neurotoxic than the dimers and trimers or oligomers isolated from brain tissue or cell

**Figure 5** Molecular mechanisms of A $\beta$  synaptotoxicity proposed in the literature. The diagram illustrates some pathways that have been invoked in different experimental paradigms to explain synaptotoxicity. It is clear that there is no agreement about what mechanism, if any, is most relevant to Alzheimer's disease. A $\beta$  directly or indirectly alters glutamate receptor-dependent cascades, thereby leading to LTP impairment and LTD facilitation. Aberrant activation of calcineurin and NFATc4 leads to the dystrophic changes in neurites, and calcineurin-dependent dephosphorylation of CaMKII impairs the induction of AMPAR-based LTP in hippocampus. Chronic exposure to A $\beta$  upregulates  $\alpha$ 7-nAChR, causing hyperactivation and then downregulation of the ERK2 (MAPK1) cascade leading to an impairment of the gene transcription-dependent phase of LTP through decreased phosphorylation of CREB factor. Some protein kinases mediate pathological phosphorylation of tau and are required for A $\beta$ -mediated synaptotoxicity. The caspase-3-mediated pathway might have a role in the A $\beta$ -mediated LTP impairment upstream of GSK-3 $\beta$ . mGluR5, metabotropic glutamate receptor 5; ERK2, extracellular signal-regulated kinase 2; MAPK, mitogen-activated protein kinase; JNK, c-Jun N-terminal kinase; Cdk5, cyclin-dependent kinase 5; GSK-3 $\beta$ , glycogen synthase kinase-3 $\beta$ ; Akt1, serine-threonine protein kinase 1; NMDAR, N-methyl-D-aspartate receptor; AMPAR,  $\alpha$ -amino-3-hydroxyl-5-methyl-4-isoxazolepropionate receptor; CaMKII, calmodulin kinase II; PKA, protein kinase A; PP1, protein phosphatase 1; NFATc4, nuclear factor of activated T-cells;  $\alpha$ 7-nAChR,  $\alpha$ 7 nicotinic acetylcholine receptor; BDNF, brain-derived neurotrophic factor; CREB, cAMP-regulatory element binding protein.



culture. For instance, cell-derived A $\beta$  oligomers can inhibit synaptic plasticity at low-nanomolar concentrations, whereas concentrations of synthetic A $\beta$  must be between two and four orders of magnitude higher to produce the same effects<sup>47</sup>. Another study shows that synthetic A $\beta$  oligomers impair complex learned behavior in rats at the same low-micromolar range as the A $\beta$ \*56 oligomers extracted from Tg2576 mouse brain, but that the synthetic oligomers remain less potent than low-*n* A $\beta$  oligomers secreted by cells<sup>48</sup>. A recent work<sup>49</sup> shows that concentrations of synthetic dimers must be two to three orders of magnitude higher than those of human brain-derived dimers to induce the same cytoskeletal impairments in primary neurons. Similar results were found for human brain-derived ASPD versus synthetic ASPD generated *in vitro*<sup>36</sup>.

The increased toxicity of these naturally derived A $\beta$  assemblies is explained by their “biologically active conformation”<sup>47</sup>, the nature of which remains, as we have discussed, elusive. It is therefore also not clear what exactly is measured when *in vitro* and *in vivo* oligomers are compared for their toxic activity. Quantitative dose-response curves and determination of specific activities (units of toxicity per unit oligomer) are needed, but the present status of the field does not allow this type of analysis.

Eventually, toxicity might be related to the heterogeneous character of natural aggregates or to unknown post-translational modifications absent in synthetic A $\beta$  preparations.

In conclusion, it is clear that as long as *in vitro* and *in vivo* approaches remain incongruent, any claim of a specific toxic A $\beta$  oligomer causing Alzheimer’s disease is difficult to replicate in other systems. This debate about the exact identity of the postulated toxic species might actually be very misleading, as it suggests implicitly that precise and specific biological mechanisms—for example, interactions of specific oligomers with specific receptors—are responsible for neurodegeneration (summarized in Figs. 4 and 5). An alternative interpretation of the available evidence is that no specific toxic oligomer exists, but that, instead, a mixture of various oligomers and aggregates (an ‘A $\beta$  soup’) is capable of interacting with cellular membranes and proteins in rather nonspecific ways (Fig. 4).

### An alternative interpretation of A $\beta$ oligomer toxicity

Many experiments investigating the mechanisms of A $\beta$  oligomer-induced toxicity indeed start from the assumption that the oligomers are stable structures that interact specifically with receptors. Further study of the synaptotoxic effects of A $\beta$  (LTP inhibition in the CA1 region of the hippocampus, dendritic spine shrinkage, LTD facilitation) has shown disturbances in the functioning of postsynaptic NMDA receptors, affecting calcium influx, a number of downstream cascades and postsynaptic AMPA receptors<sup>50</sup> (Fig. 5). Whether or not A $\beta$  oligomers directly modulate the NMDA receptor is a matter of controversy. Alternative pathways of A $\beta$ -induced synaptic failure would require an activation of the apoptotic machinery<sup>32</sup> or the upregulation of the nicotinic acetylcholine receptor  $\alpha 7$ -nAChR<sup>51</sup> (Fig. 5). Interactions with the insulin receptor<sup>52</sup>, effects on hypoxia-induced factor HIF-1 (ref. 53), clustering of the G protein-coupled angiotensin type 2 receptor and other mechanisms have also been described<sup>54</sup>. Recently, the cellular prion protein PrP<sup>C</sup> emerged as a specific receptor for toxic A $\beta$  oligomers<sup>55</sup>, which also has resulted in considerable controversy.

This brief summary of the vast literature on this topic already makes clear that no single mechanism explains all aspects of A $\beta$  oligomer toxicity. Amphiphilicity, aggregation state, covalent modifications and/or the organization of hydrophobic residues within an oligomeric assembly affect toxic effects of such oligomers. A recent work<sup>1</sup> studied a small bacterial peptide, HypF-N, which readily forms spherical oligomers, protofibrils and amyloid-like fibrils. Two types of Hyp-F

oligomers appeared very similar in atomic force microscopy and thioflavin assays, indicating similar  $\beta$ -sheet content. Nevertheless, one type of oligomer was not toxic, but the other was highly toxic. The latter interacted strongly with cellular membranes and was even able to penetrate into cells. Site-directed labeling of the oligomers using pyrene demonstrated that the toxic oligomer had a lower degree of hydrophobic packing. The authors suggested that the toxicity of the oligomers was a consequence of their structural flexibility and their hydrophobic exposure. Toxicity therefore seems a generic consequence of the amphiphilic nature of these peptides. Thus, instead of specific receptors existing for A $\beta$  toxic oligomers, it is more likely that A $\beta$  peptides will exert multiple effects by binding to membrane proteins, targeting membrane lipids, causing oxidative stress and changing membrane dielectric properties and ion permeability.

Evidence for a more generic type of toxicity is also reported by other groups<sup>26</sup>. It was found that the ongoing self-assembly of A $\beta$  to fibrils starting from soluble monomers and oligomeric seeding blocks was by itself sufficient to cause cell impairment. This finding implies that toxicity cannot be attributed to any particular A $\beta$  species but is rather caused by the nucleation-dependent dynamic fibrillogenesis process itself. Thus, aggregation-dependent A $\beta$  neurotoxicity will eventually be abrogated upon depletion of seeds or free monomers. The toxicity mechanism was suggested to be associated with the exposure of “toxic surfaces” derived from the abnormally folded peptide and their subsequent interaction with other molecules<sup>56</sup>. An analogy to prion toxicity could be made, as the kinetics of prion propagation are known to be tightly associated with prion neurotoxicity. However, according to one of the models<sup>57</sup>, the prion toxicity is attributed to an elusive “lethal” species, PrP<sup>L</sup>, possibly generated from PrP<sup>C</sup> as a toxic intermediary during rapid PrP<sup>Sc</sup> proliferation. One may speculate that this “lethal species” may be analogous to the elusive “toxic surfaces” formed by A $\beta$  during polymerization. Thus, although the hypothesis of a dynamic fibrillogenesis-associated toxicity is compatible with many of the available observations in the literature with regard to the A $\beta$  assembly process, the mechanism of toxicity remains unclear in this model as well.

### The difference between seeding, infection and toxicity

A series of elegant studies<sup>58,59</sup> demonstrates that brain extracts from people with Alzheimer’s disease or from transgenic mouse models of the disease can initiate amyloid plaque formation in the brains of transgenic APP23 mice overexpressing the Swedish-mutated human APP. The soluble extracts were made using a saline buffer, thus avoiding the potential for detergent-mediated artifacts. The extracts were injected either directly into the brain or into the peritoneal cavity. Both routes were able to induce A $\beta$  plaque deposition: thus, some mechanism must exist that enables the transference of amyloid nuclei or seeds into the brain<sup>59</sup>.

This effect can be blocked by removing A $\beta$  from the brain extracts by immunoprecipitation. These studies are remarkably congruent with the studies discussed above that used brain extracts to identify neurotoxic A $\beta$  oligomeric species, in the sense that synthetic A $\beta$  does not efficiently induce A $\beta$  amyloid formation *in vivo*<sup>58</sup>. This is, perhaps, the best experimental evidence that soluble A $\beta$  species are able to diffuse or be transported within the brain parenchyma, where they can subsequently mediate a readily measurable effect.

The observations are interesting in many ways, but further research is needed to clarify outstanding issues. For instance, the analogy with prion diseases is intriguing, but it is still unclear whether the amyloid-seeding species in the brain extracts are also able to induce A $\beta$  amyloidosis in wild-type animals. This criticism is partially addressed by a recent experiment that showed that injection of brain extract from people with Alzheimer’s disease could induce amyloid plaques in transgenic

mice overexpressing human wild-type APP that normally do not develop plaques<sup>60</sup>. There are also a few examples in the literature of monkeys injected with Alzheimer's-derived brain extracts that later developed amyloid pathology<sup>61</sup>, but at present, the number of animals is too small to make any firm conclusions about the infectivity of amyloid in Alzheimer's disease. These experiments are in fact seeding experiments, as there is no evidence of direct transmission from patient to patient or from mouse to mouse in those experiments; therefore, 'infection' should not be used to describe this phenomenon. Further work is obviously needed to address this issue more definitively, among other reasons because of the potentially enormous implications for our healthcare system (and our experimental laboratories studying Alzheimer's disease) if such transmissibility can be demonstrated.

For the present discussion, the major question to answer is what, if any, the relationship is between the soluble A $\beta$  fraction used in the seeding experiments<sup>58,59</sup> and the neurotoxic A $\beta$  oligomers isolated by other groups, as discussed above. At this moment, no link has been established between the seeded amyloidosis and possible accelerated neurodegeneration or manifestation of cognition deficits. It is likely that the presence of visible amyloid in these experiments and neurodegeneration do not entirely overlap, as is the case with prions<sup>62</sup>. Actually, if plaques are less toxic than oligomers, then accelerating amyloid formation in these experiments should improve cognitive phenotypes in the mice.

There is evidence that different morphologies of the induced amyloid fibrils and plaques exist and reflect those of the inocula used to induce them. This suggests that the amyloid seeds are polymorphic, a situation not unlike the heterogeneity of the toxic A $\beta$  oligomers discussed above. The concept of 'A $\beta$  strains' (in analogy with 'prion strains') is supported by *in vitro* experiments demonstrating that morphology and structure of A $\beta$  amyloid fibrils are self-propagating<sup>63</sup>.

In conclusion, it seems that the 'seeding A $\beta$  extracts' and the 'toxic A $\beta$  oligomer extracts' are both biochemically ill-defined mixtures of A $\beta$  peptides, and it remains unclear whether specific species are responsible for these two aspects of the disease process. It is likely that the seeding A $\beta$  species isolated from brain are in complex equilibrium with the postulated toxic A $\beta$  oligomer conformations. The structural explanation for both properties will remain, however, elusive but nevertheless important.

### Challenges for the future

For the time being, we will continue struggling with the concept of toxic A $\beta$  oligomers, and it might therefore be extremely helpful if all publications would heed recent advice regarding the communication of findings and define very precisely the methods and quality controls used in developing toxic oligomer preparations<sup>64</sup>. More comparative work and exchange of materials between laboratories would also be very helpful, as we will probably find out that many of the preparations generate very similar 'oligomer soups' (Fig. 3).

The most logical way forward, however, is to try to define more precisely the biophysical and structural properties of the toxic A $\beta$ -oligomeric fractions isolated from human brain. These 'natural' A $\beta$  preparations will probably consist of a mixture of species, and it will be virtually impossible to rule out the possibility that the toxicity ascribed to native oligomers is caused by a very small subset of toxic species, undetectable in the pool of A $\beta$ . Although this hypothesis is perfectly plausible, we should, for the time being, avoid invoking an invisible toxin, as it does not assist experimental science.

Thus, it will be necessary to define more precisely what makes an A $\beta$  oligomer preparation toxic. Some groups stabilized A $\beta$ 40 oligomers using photo-cross-linking and fractionated the different oligomers to obtain pure, stable dimers, trimers and tetramers<sup>65</sup>. On the basis of the

assumption that neurotoxic activity ( $t$ ) of an A $\beta$  assembly of order  $i$  ( $t_i$ ) is conserved between fractionated and crude populations of stabilized oligomers, a total toxic effect  $T$  of an oligomer mixture was found to depend on the frequency ( $f_i$ ) of occurrence of each particular assembly

$$T = \sum_{i=1}^n f_i t_i$$

Furthermore, a nonlinear dependence of the overall toxic effect  $t$  on oligomer order  $n$  (expressed as EC<sub>50</sub>,  $\mu$ M) was observed. The A $\beta$ 40 dimers, trimers and tetramers seemed to be 3-, 8- and 13-fold more cytotoxic, respectively, than A $\beta$ 40 monomers<sup>65</sup>. Thus, by knowing the toxicity of each assembly and the average number of oligomers in a mixed population, one should be able to predict the toxicity of a given mixture. Interestingly, toxicity in these experiments was independent of the presence of monomers, but it is still possible that the cross-linked oligomers further fibrillized into higher-order aggregates in the cellular assays. The oligomers were also initially fractionated using SDS-PAGE, and, although several purification steps were applied, the possibility of contamination by SDS complicates the interpretation of the toxicity assays. A very interesting alternative is the use of macrocyclic peptides to stabilize amyloidogenic sequences, which restrains them into  $\beta$ -strand structures but avoids further growth into fibrils<sup>66</sup>. Analysis shows that the resulting  $\beta$ -sheet dimers interact in a much more heterogeneous fashion than the parallel or antiparallel orientation observed in amyloid fibrils, providing a glimmer of insight into the heterogeneity of oligomers and a possibility of defining more precisely the nature of the oligomers tested in various biological assays<sup>66</sup>.

Further work *in vitro* will need to take into account the complexity of the A $\beta$  peptide mixture *in vivo*. Recent evidence confirms that small changes in the relative amounts of A $\beta$ 42 versus A $\beta$ 40, for instance, dramatically affect aggregation and neurotoxic properties of A $\beta$  mixtures<sup>27</sup>. Similarly, the presence of pyroglutamate A $\beta$ <sup>67</sup> or phosphorylated A $\beta$ <sup>19</sup> influences these properties. Therefore, studies using complex mixtures of the various A $\beta$  peptides mimicking the situation in the brain might be revealing. In parallel, new technologies allowing the interconversion of oligomers of different sizes to be monitored<sup>68</sup> need to be developed further.

Ideally, A $\beta$  oligomeric species that can be extracted from brain tissue should be characterized, and analytical tools that permit their identification in cerebrospinal fluid (CSF) from Alzheimer's-affected brain tissue should be developed. This would obviate the criticism that the procedure for fractionation generates, rather than extracts, the oligomeric species in question. Once fully characterized, it should be possible to synthesize the species *de novo* and show comparable biological effects.

One potentially fruitful approach to dissecting the structural heterogeneity of the toxic oligomers is the generation of conformation-specific antibodies. A wide panel of antibodies is now available<sup>44,69–87</sup> that react more specifically with oligomeric A $\beta$  than with monomeric A $\beta$ , and some do not react with A $\beta$  fibrils (Supplementary Table 1), indicating that A $\beta$  oligomers do indeed have different structural epitopes. We are, however, still far from being able to use those antibodies to distinguish specific toxic conformations. As an example, the widely used polyclonal antibody A11 recognizes a generic epitope in synthetic cytotoxic A $\beta$ 42 oligomers<sup>69</sup> and can distinguish between nontoxic 'fibrillar' and toxic 'pre-fibrillar' oligomeric assemblies<sup>44</sup>, but it does not bind  $\beta$ -sheet oligomers or protofibrils of dicysteine A $\beta$ CC that bind monoclonal antibody mAb158 (ref. 88) and does not react with the neurotoxic brain-derived ASPD (Table 1 and Supplementary Table 1)<sup>36</sup>. A further complication is that although some antibodies may recognize conformations of A $\beta$  oligomers with greater affinity than they recognize A $\beta$  monomers, the relative concentrations of



oligomers and monomers may still make such tools unsuitable for detecting oligomeric species from fluids such as CSF from patients with Alzheimer's disease. It is probable that a combination of technologies, such as immune capture with mass spectrometry, will be needed to obtain the resolution needed to perform these studies<sup>89</sup>.

Finally, the field might like to establish a set of criteria that would disprove, rather than support, the relevance of A $\beta$  oligomeric species in the Alzheimer's disease process. Given that one of the defining features of these species is that they are soluble, one should be able to detect them in the CSF of patients with Alzheimer's disease but not in controls. How can their role in Alzheimer's disease be reconciled with the effects of *APOE4* alleles and FAD mutations? Many groups demonstrate that human-derived A $\beta$  preparations can mediate various types of neuronal damage when applied to rodent neurons in culture, yet when this situation is recapitulated *in vivo*, as it is in many transgenic mice harboring human FAD *APP* genes and producing robust plaque deposition, frank neuronal loss is not demonstrated. If A $\beta$  oligomers are in equilibrium with deposited A $\beta$  plaque, one might anticipate that any neurotoxic effects would also be reflected by the topographical distribution of plaques. Thus, we have discussed some of the problems and complexity of this field, but a more fundamental question remains: do the various types of oligomeric A $\beta$  species described thus far have any role at all in the cognitive alterations and, ultimately, in the neuronal death that underpins the dementia of Alzheimer's disease?

The most promising recent avenue of research in the field is the link between A $\beta$  oligomers and tau pathology. Several groups have demonstrated that the neurotoxicity seen with different oligomer preparations is associated with tau phosphorylation and can be attenuated when the tau gene is silenced or knocked out<sup>49,90–92</sup>. However, this type of experiment, using tau abnormalities as read-outs for A $\beta$  oligomer toxicity, is at present largely descriptive. It is noteworthy that, in addition to A $\beta$  oligomers, other nonspecific cell stressors—for example, hydrogen peroxide, glutamate or serum deprivation<sup>90</sup>—could to a certain extent induce similar tau alterations. This line of research is extremely interesting, as it might eventually result in the understanding of the link between the extracellular and the intracellular amyloidosis in Alzheimer's disease.

Note: Supplementary information is available on the Nature Neuroscience website.

#### ACKNOWLEDGMENTS

The authors acknowledge funding from the European Research Council (ERC); the Fund for Scientific Research, Flanders; the University of Leuven; the VIB; the Methusalem grant from the University of Leuven and the Flemish government; the Foundation for Alzheimer Research (SAO/FDMA); and the Interuniversity Attraction Poles Program. B.D.S. is the Arthur Bax and Anna Vanluffelen Chair for Alzheimer's Disease at the University of Leuven. The authors acknowledge T. Golde, D. Teplow, T. Härd and D. Walsh for fruitful discussions and/or sharing their amyloid- $\beta$  preparations.

#### COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Published online at <http://www.nature.com/natureneuroscience/>.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

- Campioni, S. *et al.* A causative link between the structure of aberrant protein oligomers and their toxicity. *Nat. Chem. Biol.* **6**, 140–147 (2010).
- Hardy, J. & Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* **297**, 353–356 (2002).
- Karran, E., Mercken, M. & De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. *Nat. Rev. Drug Discov.* **10**, 698–712 (2011).
- De Strooper, B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. *Physiol. Rev.* **90**, 465–494 (2010).

- Castellano, J.M. *et al.* Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. *Sci. Transl. Med.* **3**, 89ra57 (2011).
- Cerf, E., Gustot, A., Goormaghtigh, E., Ruyschaert, J.M. & Raussens, V. High ability of apolipoprotein E4 to stabilize amyloid-beta peptide oligomers, the pathological entities responsible for Alzheimer's disease. *FASEB J.* **25**, 1585–1595 (2011).
- Shen, J. & Kelleher, R.J. III. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. *Proc. Natl. Acad. Sci. USA* **104**, 403–409 (2007).
- Perrin, R.J., Fagan, A.M. & Holtzman, D.M. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. *Nature* **461**, 916–922 (2009).
- Pike, C.J., Walencewicz, A.J., Glabe, C.G. & Cotman, C.W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. *Brain Res.* **563**, 311–314 (1991).
- Harper, J.D., Wong, S.S., Lieber, C.M. & Lansbury, P.T. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. *Chem. Biol.* **4**, 119–125 (1997).
- Walsh, D.M., Lomakin, A., Benedek, G.B., Condron, M.M. & Teplow, D.B. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. *J. Biol. Chem.* **272**, 22364–22372 (1997).
- Oda, T. *et al.* Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1–42) and forms slowly sedimenting A beta complexes that cause oxidative stress. *Exp. Neurol.* **136**, 22–31 (1995).
- Lambert, M.P. *et al.* Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. *Proc. Natl. Acad. Sci. USA* **95**, 6448–6453 (1998).
- Walsh, D.M. *et al.* Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation *in vivo*. *Nature* **416**, 535–539 (2002).
- McLean, C.A. *et al.* Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. *Ann. Neurol.* **46**, 860–866 (1999).
- McDonald, J.M. *et al.* The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. *Brain* **133**, 1328–1341 (2010).
- Nilsberth, C. *et al.* The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. *Nat. Neurosci.* **4**, 887–893 (2001).
- Tomiyama, T. *et al.* A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. *Ann. Neurol.* **63**, 377–387 (2008).
- Kumar, S. *et al.* Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. *EMBO J.* **30**, 2255–2265 (2011).
- Jarrett, J.T., Berger, E.P. & Lansbury, P.T. Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. *Biochemistry* **32**, 4693–4697 (1993).
- Portelius, E. *et al.* Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. *Mol. Neurodegener.* **5**, 2 (2010).
- Lee, J., Culyba, E.K., Powers, E.T. & Kelly, J.W. Amyloid-beta forms fibrils by nucleated conformational conversion of oligomers. *Nat. Chem. Biol.* **7**, 602–609 (2011).
- Bezprozvanny, I. Amyloid goes global. *Sci. Signal.* **2**, pe16 (2009).
- Bitan, G., Fradinger, E.A., Spring, S.M. & Teplow, D.B. Neurotoxic protein oligomers—what you see is not always what you get. *Amyloid* **12**, 88–95 (2005).
- Hepler, R.W. *et al.* Solution state characterization of amyloid beta-derived diffusible ligands. *Biochemistry* **45**, 15157–15167 (2006).
- Wogulis, M. *et al.* Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. *J. Neurosci.* **25**, 1071–1080 (2005).
- Kuperstein, I. *et al.* Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. *EMBO J.* **29**, 3408–3420 (2010).
- Cleary, J.P. *et al.* Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. *Nat. Neurosci.* **8**, 79–84 (2005).
- Ittner, L.M. *et al.* Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. *Cell* **142**, 387–397 (2010).
- Li, S. *et al.* Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. *Neuron* **62**, 788–801 (2009).
- Wu, H.Y. *et al.* Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. *J. Neurosci.* **30**, 2636–2649 (2010).
- Jo, J. *et al.* Abeta(1–42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3beta. *Nat. Neurosci.* **14**, 545–547 (2011).
- Hardy, J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. *J. Neurochem.* **110**, 1129–1134 (2009).
- Shankar, G.M. *et al.* Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat. Med.* **14**, 837–842 (2008).
- O'Nuallain, B. *et al.* Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. *J. Neurosci.* **30**, 14411–14419 (2010).
- Noguchi, A. *et al.* Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. *J. Biol. Chem.* **284**, 32895–32905 (2009).



37. Matsumura, S. *et al.* Two distinct amyloid  $\beta$ -protein (A $\beta$ ) assembly pathways leading to oligomers and fibrils identified by combined fluorescence correlation spectroscopy, morphology and toxicity analyses. *J. Biol. Chem.* (2011).
38. Shankar, G.M. *et al.* Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. *Neurobiol. Dis.* **36**, 293–302 (2009).
39. Lesné, S. *et al.* A specific amyloid-beta protein assembly in the brain impairs memory. *Nature* **440**, 352–357 (2006).
40. Hartley, D.M. *et al.* Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiation. *J. Biol. Chem.* **283**, 16790–16800 (2008).
41. Smith, D.P. *et al.* Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. *J. Biol. Chem.* **281**, 15145–15154 (2006).
42. Galeazzi, L., Ronchi, P., Franceschi, C. & Giunta, S. In vitro peroxidase oxidation induces stable dimers of beta-amyloid (1–42) through dityrosine bridge formation. *Amyloid* **6**, 7–13 (1999).
43. Baumketner, A. *et al.* Amyloid beta-protein monomer structure: a computational and experimental study. *Protein Sci.* **15**, 420–428 (2006).
44. Kaye, R. *et al.* Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. *Mol. Neurodegener.* **2**, 18 (2007).
45. Caughey, B. & Lansbury, P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. *Annu. Rev. Neurosci.* **26**, 267–298 (2003).
46. Hu, X. *et al.* Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. *Proc. Natl. Acad. Sci. USA* **106**, 20324–20329 (2009).
47. Townsend, M., Shankar, G.M., Mehta, T., Walsh, D.M. & Selkoe, D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. *J. Physiol. (Lond.)* **572**, 477–492 (2006).
48. Reed, M.N. *et al.* Cognitive effects of cell-derived and synthetically derived Abeta oligomers. *Neurobiol. Aging* **32**, 1784–1794 (2011).
49. Jin, M. *et al.* Soluble amyloid  $\beta$ -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. *Proc. Natl. Acad. Sci. USA* **108**, 5819–5824 (2011).
50. Yamin, G. NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus. *J. Neurosci. Res.* **87**, 1729–1736 (2009).
51. Dineley, K.T. *et al.* Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. *J. Neurosci.* **21**, 4125–4133 (2001).
52. Giuffrida, M.L. *et al.* The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology. *Rev. Neurosci.* **21**, 83–93 (2010).
53. Soucek, T., Cumming, R., Dargusch, R., Maher, P. & Schubert, D. The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. *Neuron* **39**, 43–56 (2003).
54. Thathiah, A. & De Strooper, B. G protein-coupled receptors, cholinergic dysfunction, and Abeta toxicity in Alzheimer's disease. *Sci. Signal.* **2**, re8 (2009).
55. Laurén, J., Gimbel, D.A., Nygaard, H.B., Gilbert, J.W. & Strittmatter, S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. *Nature* **457**, 1128–1132 (2009).
56. Ross, C.A. & Poirier, M.A. Opinion: What is the role of protein aggregation in neurodegeneration? *Nat. Rev. Mol. Cell Biol.* **6**, 891–898 (2005).
57. Collinge, J. & Clarke, A.R. A general model of prion strains and their pathogenicity. *Science* **318**, 930–936 (2007).
58. Meyer-Luehmann, M. *et al.* Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. *Science* **313**, 1781–1784 (2006).
59. Eisele, Y.S. *et al.* Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. *Science* **330**, 980–982 (2010).
60. Morales, R., Duran-Aniotz, C., Castilla, J., Estrada, L.D. & Soto, C. De novo induction of amyloid-beta deposition *in vivo*. *Mol. Psychiatry* (2011).
61. Baker, H.F., Ridley, R.M., Duchen, L.W., Crow, T.J. & Bruton, C.J. Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy. *Mol. Neurobiol.* **8**, 25–39 (1994).
62. Aguzzi, A. & Calella, A.M. Prions: protein aggregation and infectious diseases. *Physiol. Rev.* **89**, 1105–1152 (2009).
63. Petkova, A.T. *et al.* Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. *Science* **307**, 262–265 (2005).
64. Anonymous. State of aggregation. *Nat. Neurosci.* **14**, 399 (2011).
65. Ono, K., Condron, M.M. & Teplow, D.B. Structure-neurotoxicity relationships of amyloid  $\beta$ -protein oligomers. *Proc. Natl. Acad. Sci. USA* **106**, 14745–14750 (2009).
66. Liu, C. *et al.* Characteristics of amyloid-related oligomers revealed by crystal structures of macrocyclic beta-sheet mimics. *J. Am. Chem. Soc.* **133**, 6736–6744 (2011).
67. Schlenzig, D. *et al.* Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. *Biochemistry* **48**, 7072–7078 (2009).
68. Bleiholder, C., Dupuis, N.F., Wyttenbach, T. & Bowers, M.T. Ion mobility-mass spectrometry reveals a conformational conversion from random assembly to beta-sheet in amyloid fibril formation. *Nat. Chem.* **3**, 172–177 (2011).
69. Kaye, R. *et al.* Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science* **300**, 486–489 (2003).
70. Shughrue, P.J. *et al.* Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. *Neurobiol. Aging* **31**, 189–202 (2010).
71. O'Nuallain, B. *et al.* A monoclonal antibody against synthetic Abeta dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Abeta. *J. Neurochem.* **119**, 189–201 (2011).
72. Lambert, M.P. *et al.* Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. *J. Neurochem.* **79**, 595–605 (2001).
73. Lambert, M.P. *et al.* Monoclonal antibodies that target pathological assemblies of Abeta. *J. Neurochem.* **100**, 23–35 (2007).
74. Lee, E.B. *et al.* Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. *J. Biol. Chem.* **281**, 4292–4299 (2006).
75. Moretto, N. *et al.* Conformation-sensitive antibodies against Alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. *J. Biol. Chem.* **282**, 11436–11445 (2007).
76. Schupf, N. *et al.* Peripheral Abeta subtypes as risk biomarkers of Alzheimer's disease. *Proc. Natl. Acad. Sci. USA* **105**, 14052–14057 (2008).
77. Gardberg, A.S. *et al.* Molecular basis for passive immunotherapy of Alzheimer's disease. *Proc. Natl. Acad. Sci. USA* **104**, 15659–15664 (2007).
78. Englund, H. *et al.* Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. *J. Neurochem.* **103**, 334–345 (2007).
79. Lord, A. *et al.* An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. *Neurobiol. Dis.* **36**, 425–434 (2009).
80. Hillen, H. *et al.* Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. *J. Neurosci.* **30**, 10369–10379 (2010).
81. O'Nuallain, B. & Wetzel, R. Conformational Abs recognizing a generic amyloid fibril epitope. *Proc. Natl. Acad. Sci. USA* **99**, 1485–1490 (2002).
82. Barghorn, S. *et al.* Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. *J. Neurochem.* **95**, 834–847 (2005).
83. van Helmond, Z., Heesom, K. & Love, S. Characterisation of two antibodies to oligomeric Abeta and their use in ELISAs on human brain tissue homogenates. *J. Neurosci. Methods* **176**, 206–212 (2009).
84. Habicht, G. *et al.* Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. *Proc. Natl. Acad. Sci. USA* **104**, 19232–19237 (2007).
85. Lafaye, P., Achour, I., England, P., Duyckaerts, C. & Rougeon, F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. *Mol. Immunol.* **46**, 695–704 (2009).
86. Meli, G., Visintin, M., Cannistraci, I. & Cattaneo, A. Direct *in vivo* intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers. *J. Mol. Biol.* **387**, 584–606 (2009).
87. Zameer, A., Kasturirangan, S., Emadi, S., Nimmagadda, S.V. & Sierks, M.R. Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. *J. Mol. Biol.* **384**, 917–928 (2008).
88. Sandberg, A. *et al.* Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering. *Proc. Natl. Acad. Sci. USA* **107**, 15595–15600 (2010).
89. Villemagne, V.L. *et al.* Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease. *J. Neurosci.* **30**, 6315–6322 (2010).
90. Zempel, H., Thies, E., Mandelkow, E. & Mandelkow, E.M. Abeta oligomers cause localized Ca(2+) elevation, misrouting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. *J. Neurosci.* **30**, 11938–11950 (2010).
91. Shipton, O.A. *et al.* Tau protein is required for amyloid  $\beta$ -induced impairment of hippocampal long-term potentiation. *J. Neurosci.* **31**, 1688–1692 (2011).
92. De Felice, F.G. *et al.* Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. *Neurobiol. Aging* **29**, 1334–1347 (2008).
93. Wang, X., Perry, G., Smith, M.A. & Zhu, X. Amyloid-beta-derived diffusible ligands cause impaired axonal transport of mitochondria in neurons. *Neurodegener. Dis.* **7**, 56–59 (2010).
94. Demuro, A. *et al.* Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. *J. Biol. Chem.* **280**, 17294–17300 (2005).
95. Deshpande, A., Mina, E., Glabe, C. & Busciglio, J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. *J. Neurosci.* **26**, 6011–6018 (2006).
96. Lasagna-Reeves, C.A., Glabe, C.G. & Kaye, R. Amyloid- $\beta$  annular protofibrils evade fibrillar fate in Alzheimer's disease brain. *J. Biol. Chem.* (2011).
97. Xia, W. *et al.* Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. *J. Biol. Chem.* **272**, 7977–7982 (1997).
98. Podlisky, M.B. *et al.* Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. *J. Biol. Chem.* **270**, 9564–9570 (1995).
99. Roher, A.E. *et al.* Morphology and toxicity of Abeta(1–42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. *J. Biol. Chem.* **271**, 20631–20635 (1996).
100. Hoshi, M. *et al.* Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. *Proc. Natl. Acad. Sci. USA* **100**, 6370–6375 (2003).